Dr. Reddy's Laboratories, Inc.

117 articles with Dr. Reddy's Laboratories, Inc.

• 

  Clinical Catch-Up: January 25-29

  2/1/2021

  It was a busy week for clinical trial news. Read on for more information.

• Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies

  1/27/2021

  Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and Global Response Aid FZCO (GRA) today announced results from an Avigan study on moderate-severe hospitalized COVID-19 patients in Kuwait.

• Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India

  1/15/2021

  Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlie

• Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.

• Dr. Reddy's to Release Q3 FY 21 Results on January 29th, 2021

  1/8/2021

  Dr. Reddy's Laboratories Ltd. will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting.

• 

  Biopharma Update on the Novel Coronavirus: December 1

  12/1/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.

• Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

  11/12/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administratio

• Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

  10/12/2020

  Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting.

• 

  Clinical Catch-Up: September 21-25

  9/28/2020

  The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

• Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

  9/17/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.

• 

  Biopharma Update on the Novel Coronavirus: September 16

  9/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.

• Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.  

  7/27/2020

  Dr. Reddy’s Laboratories Ltd. announced approval of XEGLYZE lotion, 0.74%, a 505 NDA by the U.S. Food and Drug Administration. The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty Ltd.

• Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020

  7/20/2020

  Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the first quarter ended June 30, 2020 on Wednesday, July 29th, 2020 after the Board Meeting.

• 

  Biopharma Update on the Novel Coronavirus: June 15

  6/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.

• Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir

  6/13/2020

  Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register, manu

• Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.

  5/6/2020

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced approval of ELYXYB (celecoxib oral solution 25 mg/mL) by the U.S. Food and Drug Administration (USFDA). ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.

• Dr. Reddy's Laboratories Issues Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening

  3/26/2020

  Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level.

• Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States

  3/4/2020

  Nuvo Pharmaceuticals Inc., a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Dr. Reddy's Laboratories Inc. has launched its generic version of Vimovo in the United States.

• Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

  2/4/2019

  Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.

• Neurelis Announces First Product Approved Using The Company's Intravail® Platform

  1/30/2019

  Dr. Reddy's Laboratories and its U.S. subsidiary, Promius Pharma, announced U.S. FDA approval on January 28 for its migraine treatment TOSYMRA™ in the United States